Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Therapeutic applications of mesenchymal stroma cells in pediatric diseases: current aspects and future perspectives

Habib HS., Halawa TF., Atta HM.

Clinical Trial on Autoimmune Research, published in Med Sci Monit (2011) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Med Sci Monit (2011)
Reported sample size
—
Source database
Europe PMC
PMID
22037754
PMCID
PMC3539490
DOI
10.12659/msm.882036
Citations
6

Abstract (original English)

Mesenchymal stem cells or stroma cells (MSCs) were recently proven to play various therapeutic roles when used in clinical trials to control various inflammatory, neoplastic and immunologic diseases in children. Clinical trials show some promising results, particularly in diseases where conventional therapy is still ineffective. However, experimental studies sometimes show conflicting results. This review aims to assess the current therapeutic role of MSCs in the control of several pediatric diseases and elaborate on their future applications by reviewing published studies. A review of published studies on this subject based on Pubmed and Medical Subject Heading databases, with search for all relevant articles focusing on results of clinical trials to evaluate the clinical applications of MSCs. The review includes documentation of positive as well as negative applications of MSCs focused on pediatric diseases. MSCs have important immunosuppressive and antifibrotic effects that need to be employed to help patients with diseases for which no conventional management has proven to be effective. They may be also be used as an adjuvant to conventional therapeutic modalities to consolidate recovery. This review sheds light on the significance of the use of MSCs for the treatment of various pediatric diseases and focuses on promising applications. Most of the reported studies agree abo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansMusculoskeletal DiseasesLung DiseasesCardiovascular DiseasesAnemia, AplasticDiabetes Mellitus, Type 1Autoimmune DiseasesGraft vs Host DiseaseMesenchymal Stem Cell TransplantationPediatrics

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research